NASDAQ:SWTX SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis $38.04 +1.17 (+3.17%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$36.73▼$38.6750-Day Range$36.06▼$44.2752-Week Range$18.00▼$53.92Volume515,590 shsAverage Volume975,845 shsMarket Capitalization$2.82 billionP/E RatioN/ADividend YieldN/APrice Target$68.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get SpringWorks Therapeutics alerts: Email Address SpringWorks Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside80.9% Upside$68.83 Price TargetShort InterestBearish14.25% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.62) to ($3.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.31 out of 5 starsMedical Sector781st out of 936 stocksBiological Products, Except Diagnostic Industry134th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingSpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSpringWorks Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about SpringWorks Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.25% of the outstanding shares of SpringWorks Therapeutics have been sold short.Short Interest Ratio / Days to CoverSpringWorks Therapeutics has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.Change versus previous monthShort interest in SpringWorks Therapeutics has recently increased by 1.34%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSpringWorks Therapeutics does not currently pay a dividend.Dividend GrowthSpringWorks Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SWTX. Previous Next 3.9 News and Social Media Coverage News SentimentSpringWorks Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for SpringWorks Therapeutics this week, compared to 3 articles on an average week.Search Interest4 people have searched for SWTX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows3 people have added SpringWorks Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SpringWorks Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.61% of the stock of SpringWorks Therapeutics is held by insiders.Read more about SpringWorks Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($4.62) to ($3.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SpringWorks Therapeutics is -7.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SpringWorks Therapeutics is -7.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpringWorks Therapeutics has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about SpringWorks Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About SpringWorks Therapeutics Stock (NASDAQ:SWTX)SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.Read More SWTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SWTX Stock News HeadlinesJuly 25 at 1:21 AM | americanbankingnews.comAnalyzing SpringWorks Therapeutics (NASDAQ:SWTX) & ADMA Biologics (NASDAQ:ADMA)July 23 at 7:00 AM | globenewswire.comSpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024July 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.July 2, 2024 | prnewswire.comKuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law FirmJuly 1, 2024 | globenewswire.comSpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PNJune 5, 2024 | globenewswire.comSpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 27, 2024 | investing.comSpringWorks Therapeutics Inc (SWTX)May 23, 2024 | globenewswire.comSpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.May 23, 2024 | benzinga.comSpringWorks Therapeutics Stock (NASDAQ:SWTX), Quotes and News SummaryMay 8, 2024 | globenewswire.comSpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care ConferenceMay 6, 2024 | markets.businessinsider.comStrong Buy Rating for Springworks Therapeutics Amidst Ogsiveo’s Market Success and Robust PipelineMay 6, 2024 | msn.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q1 2024 Earnings Call TranscriptMay 5, 2024 | seekingalpha.comSpringWorks Therapeutics, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 3, 2024 | finance.yahoo.comSpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 3, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn SituationMay 2, 2024 | markets.businessinsider.comBuy Rating for Springworks Therapeutics Amid Strong Market Performance and Promising PipelineMay 2, 2024 | investorplace.comSWTX Stock Earnings: SpringWorks Therapeutics Meets EPS, Beats Revenue for Q1 2024See More Headlines Receive SWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SWTX CUSIPN/A CIK1773427 Webwww.springworkstx.com Phone203-883-9490FaxN/AEmployees230Year Founded2017Price Target and Rating Average Stock Price Target$68.83 High Stock Price Target$75.00 Low Stock Price Target$52.00 Potential Upside/Downside+84.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-325,100,000.00 Net MarginsN/A Pretax Margin-1,281.78% Return on Equity-66.48% Return on Assets-57.28% Debt Debt-to-Equity RatioN/A Current Ratio6.85 Quick Ratio6.77 Sales & Book Value Annual Sales$5.45 million Price / Sales505.99 Cash FlowN/A Price / Cash FlowN/A Book Value$10.01 per share Price / Book3.72Miscellaneous Outstanding Shares74,090,000Free Float68,448,000Market Cap$2.76 billion OptionableOptionable Beta0.78 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Francis I. Perier Jr. (Age 64)M.B.A., Chief Financial Officer Comp: $768.24kDr. Badreddin Edris Ph.D. (Age 37)Chief Operating Officer Comp: $1.02MDr. James Cassidy M.D. (Age 64)Ph.D., Chief Medical Officer Comp: $904.25kMr. Michael P. Nofi (Age 53)Chief Accounting Officer Mr. Tai-An Lin Ph.D.Chief Scientific OfficerMs. Kim DiamondVice President of Communications & Investor RelationsMr. Herschel S. Weinstein J.D. (Age 67)General Counsel & Secretary Comp: $568.64kMr. Daniel J. Pichl (Age 40)Chief People Officer Comp: $428.51kMr. Bhavesh Ashar M.B.A. (Age 58)Chief Commercial Officer Comp: $729.62kMore ExecutivesKey CompetitorsBeam TherapeuticsNASDAQ:BEAMVir BiotechnologyNASDAQ:VIRChina Biologic ProductsNASDAQ:CBPOAllogene TherapeuticsNASDAQ:ALLOReplimune GroupNASDAQ:REPLView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 66,161 shares on 7/26/2024Ownership: 0.404%Allspring Global Investments Holdings LLCBought 3,278 shares on 7/26/2024Ownership: 0.004%Calamos Advisors LLCSold 17,604 shares on 7/25/2024Ownership: 0.010%Hennion & Walsh Asset Management Inc.Sold 314 shares on 7/20/2024Ownership: 0.050%First Horizon Advisors Inc.Bought 383 shares on 7/20/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions SWTX Stock Analysis - Frequently Asked Questions How have SWTX shares performed this year? SpringWorks Therapeutics' stock was trading at $36.50 at the beginning of 2024. Since then, SWTX stock has increased by 4.2% and is now trading at $38.04. View the best growth stocks for 2024 here. How were SpringWorks Therapeutics' earnings last quarter? SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) posted its quarterly earnings results on Thursday, May, 2nd. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by $0.01. SpringWorks Therapeutics's revenue was up 2000.0% on a year-over-year basis. Does SpringWorks Therapeutics have any subsidiaries? The following companies are subsidiaries of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc.. When did SpringWorks Therapeutics IPO? SpringWorks Therapeutics (SWTX) raised $126 million in an initial public offering on Friday, September 13th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are SpringWorks Therapeutics' major shareholders? Top institutional investors of SpringWorks Therapeutics include Bank of New York Mellon Corp (0.40%), Hennion & Walsh Asset Management Inc. (0.05%), DNB Asset Management AS (0.02%) and China Universal Asset Management Co. Ltd. (0.01%). Insiders that own company stock include Orbimed Advisors Llc, Daniel Pichl, Julie Hambleton, Bain Capital Life Sciences Inv, Saqib Islam and L Mary Smith. View institutional ownership trends. How do I buy shares of SpringWorks Therapeutics? Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of SpringWorks Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Johnson & Johnson (JNJ), Albireo Pharma (ALBO), Gilead Sciences (GILD), Sunrun (RUN) and Alnylam Pharmaceuticals (ALNY). This page (NASDAQ:SWTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SpringWorks Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.